Rachel V. Brady, DVM, DACVIM (Oncology)
Rachel V. Brady, DVM (CHF Grant 03033-E)
Mentors: Dawn Duval, PhD; Steven Dow, DVM, PhD, DACVIM; and Douglas Thamm, VMD, DACVIM (Oncology); Colorado State University
After volunteering with the US Peace Corps, Dr. Brady earned her veterinary degree from the University of California, Davis School of Veterinary Medicine. She completed a small animal rotating internship at North Carolina State University College of Veterinary Medicine and returned to UC, Davis for a Medical Oncology Residency. She is now a doctoral student in the Cell and Molecular Biology Graduate Program at Colorado State University (CSU).
As part of her doctoral training, Dr. Brady will rotate through the laboratories of Drs. Dawn Duval (Molecular Oncology), Douglas Thamm (Cancer Biology and Developmental Therapeutics) and Steven Dow (Tumor Immunology) at CSU’s Flint Animal Cancer Center. She will work with cell models for cancers that impact both people and dogs, including diffuse large B-cell lymphoma (DLBCL) and osteosarcoma (bone cancer), in order to identify biomarkers and potential treatment targets.
Dr. Brady hopes to work in translational research, bridging human and animal health at an academic institution or large cancer center.
This fellowship is generously sponsored by the Orthopedic Foundation for Animals (OFA).
Dr. Brady’s mentors have received prior CHF funding for oncology research. Read about their research:
591: In Vitro Effects of the Milk Thistle Extract Silibinin in Canine Tumor Cells
01064-A: Immunocytochemical Detection and siRNA-Mediated Knockdown of Survivin in Canine Lymphoma
01152: Liposomal Bisphosphonate Therapy for Malignant Histiocytosis
01426: Personalized Medicine for the Treatment of Canine Mast Cell Tumors
01472: Enhanced Killing of Malignant Histiocytosis with a Novel Combination of Anti-Tumor Drugs
01569: Evaluation of a Novel Drug to Treat Canine Cutaneous Lymphoma
01876-A: Ensuring That Emerging Stem Cell Treatments Do Not Activate or Exacerbate Cancer in Dogs
02487: OX40 Checkpoint Molecule Targeted Antibodies for Cancer Immunotherapy in Dogs
02910: Open-Label, Phase-2 Clinical Trial of Chlorambucil and Toceranib for Canine Mast Cell Tumors
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.
